LMP1 structure and signal transduction

Seminars in Cancer Biology

Volumn 11, Issue 6, 2001, Pages 435-444

  Eliopoulos, Aristides G ^a   Young, Lawrence S ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

CD40; EBV; LMP1; Signalling

Indexed keywords

GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CDC42; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RECEPTOR;

CELL TRANSFORMATION; EPSTEIN BARR VIRUS; HUMAN; LYMPHOMA; MOLECULAR INTERACTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; VIRUS CARCINOGENESIS;

EID: 0035192960     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0410     Document Type: Article

References (65)

1. Epstein-Barr virus
2. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
3. Epstein-Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation
4. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which stimulates an activated CD40 receptor
5. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation
6. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6
7. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice
8. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis
9. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus oncoprotein LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line
10. Induction of bcl-2 expression by the Epstein-Barr-Virus Latent Membrane Protein-1 protects infected B-cells from programmed cell death
11. Involvement of two NF-κB binding elements in tumor necrosis factor alpha-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene
12. The Epstein-Barr Virus LMP-1 product induces A20 zinc finger protein expression by activating nuclear factor-B
13. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B cell lines
14. LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16(INK4a) expression
15. Activation of the p38 MAPK pathway by Epstein-Barr virus encoded latent membrane protein 1 (LMP1) co-regulates interleukin-6 and interleukin-8 production
16. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1
17. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth
18. High concentration of the EBV Latent Membrane Protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells
19. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts
20. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation: Fibroblast cocultivation complements a critical function within the terminal 155 residues
21. The Epstein-Barr Virus latent membrane protein 1 (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain
22. The Epstein-Barr virus oncoprotein Latent Membrane protein 1 engages the tumour necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-κB activation
23. The Epstein-Barr virus LMP1 amino acid sequence that engages tumour necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation
24. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation
25. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumour necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kB
26. The Epstein-Barr virus transforming protein LMP-1 engages signaling proteins for the tumour necrosis factor receptor family
27. Mimicry of CD40 signals by Epstein Barr virus LMP1 in B lymphocyte responses
28. TRAF1, TRAF2 and TRAF3 effect NF-kB activation by an Epstein-Barr Virus LMP1 domain important for B lymphocyte transformation
29. Tumour necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein
30. Localization of the major NF-kB-activating site and the sole TRAF3 binding site of LMP1 defines two distinct signaling motifs
31. Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression
32. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40
33. Comparative analysis identifies conserved tumour necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1
34. The structural basis for the recognition of diverse receptor sequences by TRAF2
35. Thermodynamic characterisation of the interaction between TRAF2 and tumour necrosis factor receptor peptides by isothermal titration calorimetry
36. LMP1 signal transduction differs substantially from TNF receptor 1 signalling in the molecular functions of TRADD and TRAF2
37. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation
38. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
39. NF-κB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cell lines
40. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kB activity
41. Nuclear factor-kappa B activation involved in LMP1-mediated transformation and tumorigenesis of Rat-1 fibroblasts
42. Stimulation of NF-kB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus
43. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerization for NF-kB activation
44. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule
45. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant Cao regulates enhanced signaling activity
46. LMP1 activates NF-kB by targeting the inhibitory molecule IκBα
47. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-κB/Rel family proteins
48. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator
49. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kB pathway involving TNF receptor-associated factors
50. Epstein-Barr virus-transforming protein latent membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ
51. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway via a mechanism involving TRADD and TRAF2
52. Effects of the NIK only mutation on NF-KB activating by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor and CD40
53. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
54. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)
55. A fusion of the Epstein-Barr virus latent membrane protein 1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor expression. NF-kB and stress-activated protein kinase
56. Mechanism of action of a novel latent membrane protein 1 dominant negative
57. The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex
58. The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway
59. Activation of a Ras-MAPK-dependent pathway by Epstein-Barr Virus latent membrane protein 1 is essential for cellular transformation
60. Divergent requirements for the MAPK/ERK signal transduction pathway during initial virus infection of quiescent primary B cells and disruption of Epstein Barr virus latency by phorbol esters
61. Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions
62. Activation of the small GTPase Cdc42 by the inflammatory cytokines TNFα and IL-1, and by the Epstein-Barr virus transforming protein LMP1
63. Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PxQxT motif is essential for induction of epidermal growth factor receptor expression
64. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong
65. Comparative analysis of Epstein-Barr virus gene polymorphisms in nasal T/NK cell lymphomas and normal nasal tissues: Implications on virus strain selection in malignancy